1 / 7

Lu-PSMA Therapy A Breakthrough in Prostate Cancer Treatment

Lu-PSMA therapy is a targeted radioligand treatment that uses Lutetium-177 linked to a molecule binding to the PSMA protein, which is highly expressed in prostate cancer cells. This innovative approach delivers precise radiation directly to cancer cells while sparing surrounding healthy tissue. Clinical studies have shown significant PSA declines, improved survival rates, and better quality of life in patients with advanced prostate cancer, especially those resistant to conventional treatments. It represents a major advancement in nuclear medicine ... more info: https://nuclearmedicinetherapy.

Nuclearmedicinetherapy
Download Presentation

Lu-PSMA Therapy A Breakthrough in Prostate Cancer Treatment

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Nuclear Medicine Centre FMRi Gurugram INDIA Dr. Ishita B Sen Lu-PSMA Therapy: A Breakthrough in Prostate Cancer Treatment www.nuclearmedicinetherapy.in

  2. What is Lu-PSMA Therapy? • Lu-PSMA = Lutetium-177 labeled PSMA ligand therapy • Targets PSMA receptors overexpressed on prostate cancer cells • Delivers beta radiation precisely to cancerous tissues • Minimizes damage to surrounding healthy cells

  3. Key Benefits of Lu-PSMA Therapy • Targets only PSMA-positive cells • Effective for metastatic castration-resistant prostate cancer (mCRPC) • Non-invasive with minimal side effects • Improves quality of life and survival

  4. Treatment Process • Patient selection – via PSMA PET scan • Intravenous injection of Lu-177 PSMA ligand • Targeted irradiation of cancer cells • Periodic monitoring for response and safety

  5. Clinical Success & Patient Impact • Shown to reduce PSA levels in 70–80% of patients • Helps manage late-stage and treatment-resistant cases • Enhances progression-free and overall survival • Well-tolerated with manageable side effects

  6. Conclusion • Alpha PRRT with Actinium-225 represents a significant advancement in the treatment of NETs, offering higher efficacy and a better safety profile compared to traditional beta-emitting therapies. • Future Outlook: Continued research and clinical trials are expected to further establish its role in standard care protocols for NETs.​

  7. For more information talk to Dr. Ishita B Sen today. dr.ishitasen@nuclearmedicinetherapy.in +91 8700 668 431 www.nuclearmedicinetherapy.in

More Related